Particulate formulations for the delivery of poly(I: C) as vaccine adjuvant

Advanced Drug Delivery Reviews

Volumn 65, Issue 10, 2013, Pages 1386-1399

  Hafner, Annina M ^a   Corthésy, Blaise ^b   Merkle, Hans P ^a  

^a ETH ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Autoimmunity; Dendritic cells; Efficacy; Immunostimulation; Microspheres; Non professional phagocytes; Safety; Surface modification; TLR3 ligands; Vaccine formulations

Indexed keywords

AUTOIMMUNITY; DENDRITIC CELLS; EFFICACY; IMMUNOSTIMULATION; NON-PROFESSIONAL PHAGOCYTES;

ACCIDENT PREVENTION; ANTIGENS; LIPOSOMES; MICROSPHERES; SURFACE TREATMENT; VACCINES; WELL STIMULATION;

CELL SIGNALING;

DOUBLE STRANDED RNA; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MICROSPHERE; NANOPARTICLE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CELL FUNCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; ENCAPSULATION; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ABSENT-IN-MELANOMA 2; AIM 2; AMPLIGEN; ANTIGEN-PRESENTING CELL; APC; AUTOIMMUNITY; BMDC; BONE MARROW-DERIVED DC; C-TYPE LECTIN RECEPTOR; CETYTRIMETHYLAMMONIUM BROMIDE; CLR; CTAB; CTL; CYTOTOXIC T LYMPHOCYTE; DAI; DAMP; DANGER-ASSOCIATED MOLECULAR PATTERN; DC; DDA; DEAE; DENDRITIC CELL; DENDRITIC CELLS; DIETHYLAMINOETHYL; DIMETHYLDIOCTADECYLAMMONIUM; DNA-DEPENDENT ACTIVATOR OF IFN-REGULATORY FACTOR; DOUBLE-STRANDED; DS; EFFICACY; GM-CSF; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR; HFF; HUMAN FORESKIN FIBROBLAST; IDCS; IFN; IFN-REGULATORY FACTOR 3; IFN-Γ-INDUCIBLE PROTEIN 10 (CXCL10); IL; IMMATURE DCS; IMMUNOSTIMULATION; INTERFERON; INTERLEUKIN; IP 10; IRF 3; LANGERHANS CELLS; LCS; LIPOPOLYSACCHARIDE; LPS; M720; MACROPHAGE-INDUCIBLE C TYPE LECTIN; MAJOR HISTOCOMPATIBILITY COMPLEX; MATURE DC; MDA-5; MDC; MELANOMA DIFFERENTIATION-ASSOCIATED GENE-5; MHC; MICROSPHERES; MINCLE; MODC; MONOCYTE-DERIVED DENDRITIC CELL; MONTANIDE ISA 720; NAP 1; NEUTROPHIL ACTIVATING PEPTIDE 1; NLR; NOD-LIKE RECEPTOR; NON-PROFESSIONAL PHAGOCYTES; ODN; OLIGODEOXYNUCLEOTIDE; OVA; OVALBUMIN; PAMP; PATHOGEN RECOGNITION RECEPTOR; PATHOGEN-ASSOCIATED MOLECULAR PATTERN; PDC; PEG; PEI; PH-SENSITIVE POLYKETAL COPOLYMER; PK3; PLASMACYTOID DENDRITIC CELL; PLGA; PLL; PLL-G-PEG; POLY(A:U); POLY(ETHYLENE GLYCOL); POLY(I:C); POLY(I:C) STABILIZED WITH POLY(L-LYSINE) AND CARBOXYMETHYLCELLULOSE; POLY(I:C12U); POLY(IC·LC); POLY(L-LYSINE); POLY(L-LYSINE)-GRAFT-POLY(ETHYLENE GLYCOL); POLY(LACTIC-CO-GLYCOLIC ACID); POLYETHYLENEIMINE; POLYRIBOADENYLIC-POLYRIBOURIDYLIC ACID; POLYRIBOINOSINIC ACID-POLYRIBOCYTIDYLIC ACID; POLYSTYRENE; PRR; PS; RETINOIC ACID-INDUCIBLE GENE-I; RETINOIC ACID-INDUCIBLE GENE-I-LIKE RECEPTORS; RIG I; RLRS; SAFETY; SLN; SOLID-LIPID NANOPARTICLE; SURFACE MODIFICATION; T CELL RECEPTOR; TCR; TDB; TLR; TLR3 LIGANDS; TNF-Α; TOLL-LIKE RECEPTOR; TREHALOSE 6,6′-DIBEHENATE; TUMOR NECROSIS FACTOR-ALPHA; VACCINE FORMULATIONS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; DENDRITIC CELLS; HUMANS; MICROSPHERES; POLY I-C; TOLL-LIKE RECEPTOR 3; VACCINES;

EID: 84885378665     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.05.013     Document Type: Review

References (170)

1. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev. Vaccines 2011, 10:539-550.
2. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants - a brief overview. Immunol. Lett. 2010, 128:29-35.
3. De Temmerman M.L., Rejman J., Demeester J., Irvine D.J., Gander B., De Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov. Today 2011, 16:569-582.
4. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
5. Kayamuro H., Abe Y., Yoshioka Y., Katayama K., Nomura T., Yoshida T., Yamashita K., Yoshikawa T., Kawai Y., Mayumi T., Hiroi T., Itoh N., Nagano K., Kamada H., Tsunoda S., Tsutsumi Y. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 2009, 30:5869-5876.
6. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
7. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5:505-517.
8. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
9. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
10. Mutwiri G., Gerdts V., van Drunen Littel-van den Hurk S., Auray G., Eng N., Garlapati S., Babiuk L.A., Potter A. Combination adjuvants: the next generation of adjuvants?. Expert Rev. Vaccines 2011, 10:95-107.
11. Desmet C.J., Ishii K.J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 2012, 12:479-491.
12. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
13. Naik S.H. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 2008, 86:439-452.
14. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 2007, 7:19-30.
15. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
16. Granucci F., Foti M., Ricciardi-Castagnoli P. Dendritic cell biology. Adv. Immunol. 2005, 88:193-233.
17. Schreibelt G., Tel J., Sliepen K.H., Benitez-Ribas D., Figdor C.G., Adema G.J., de Vries I.J. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 2010, 59:1573-1582.
18. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179:1109-1118.
19. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30:16-34.
20. Belkaid Y., Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008, 29:362-371.
21. Ma X., Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 2001, 79:55-92.
22. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
23. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 2003, 3:984-993.
24. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101:311-320.
25. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
26. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 2010, 40:1830-1835.
27. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
28. + T cell activation and CTL effector function. J. Immunol. 2002, 168:3786-3792.
29. Modlin R.L. Th1-Th2 paradigm: insights from leprosy. J. Invest. Dermatol. 1994, 102:828-832.
30. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol. 2010, 22:411-416.
31. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
32. Ito T., Wang Y.H., Liu Y.J. Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin. Immunopathol. 2005, 26:221-229.
33. Mempel M., Voelcker V., Kollisch G., Plank C., Rad R., Gerhard M., Schnopp C., Fraunberger P., Walli A.K., Ring J., Abeck D., Ollert M. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is Toll-like receptor 2 but not Toll-like receptor 4 or platelet activating factor receptor dependent. J. Invest. Dermatol. 2003, 121:1389-1396.
34. Heinz S., Haehnel V., Karaghiosoff M., Schwarzfischer L., Muller M., Krause S.W., Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J. Biol. Chem. 2003, 278:21502-21509.
35. Lundberg A.M., Drexler S.K., Monaco C., Williams L.M., Sacre S.M., Feldmann M., Foxwell B.M. Key differences in TLR3/poly(I:C) signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 2007, 110:3245-3252.
36. Matsumoto M., Funami K., Tanabe M., Oshiumi H., Shingai M., Seto Y., Yamamoto A., Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 2003, 171:3154-3162.
37. Flacher V., Bouschbacher M., Verronese E., Massacrier C., Sisirak V., Berthier-Vergnes O., de Saint-Vis B., Caux C., Dezutter-Dambuyant C., Lebecque S., Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 2006, 177:7959-7967.
38. Ospelt C., Brentano F., Rengel Y., Stanczyk J., Kolling C., Tak P.P., Gay R.E., Gay S., Kyburz D. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008, 58:3684-3692.
39. Harwani S.C., Lurain N.S., Zariffard M.R., Spear G.T. Differential inhibition of human cytomegalovirus (HCMV) by Toll-like receptor ligands mediated by interferon-beta in human foreskin fibroblasts and cervical tissue. Virol. J. 2007, 4.
40. Matsumoto M., Kikkawa S., Kohase M., Miyake K., Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 2002, 293:1364-1369.
41. Schreiner B., Voss J., Wischhusen J., Dombrowski Y., Steinle A., Lochmuller H., Dalakas M., Melms A., Wiendl H. Expression of Toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J. 2006, 20:118-120.
42. Begon E., Michel L., Flageul B., Beaudoin I., Jean-Louis F., Bachelez H., Dubertret L., Musette P. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur. J. Dermatol. 2007, 17:497-506.
43. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68:7010-7017.
44. Funami K., Sasai M., Ohba Y., Oshiumi H., Seya T., Matsumoto M. Spatiotemporal mobilization of Toll/IL-1 receptor domain-containing adaptor molecule-1 in response to dsRNA. J. Immunol. 2007, 179:6867-6872.
45. Takeuchi O., Akira S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 2008, 20:17-22.
46. Lech M., Avila-Ferrufino A., Skuginna V., Susanti H.E., Anders H.J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int. Immunol. 2010, 22:717-728.
47. Siren J., Imaizumi T., Sarkar D., Pietila T., Noah D.L., Lin R., Hiscott J., Krug R.M., Fisher P.B., Julkunen I., Matikainen S. Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines. Microbes Infect. 2006, 8:2013-2020.
48. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505.
49. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., Fitzgerald K.A., Paludan S.R., Bowie A.G. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004.
50. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., Latz E., Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
51. +/+ mice display similar immune responses to a DNA vaccine. Immunology 2004, 113:114-120.
52. Schmidt C. Clinical setbacks for Toll-like receptor 9 agonists in cancer. Nat. Biotechnol. 2007, 25:825-826.
53. Leonard J.N., Ghirlando R., Askins J., Bell J.K., Margulies D.H., Davies D.R., Segal D.M. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:258-263.
54. Okahira S., Nishikawa F., Nishikawa S., Akazawa T., Seya T., Matsumoto M. Interferon-beta induction through Toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol. 2005, 24:614-623.
55. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
56. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
57. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., Endres S., Hartmann G. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
58. Li X., Lu C., Stewart M., Xu H., Strong R.K., Igumenova T., Li P. Structural basis of double-stranded RNA recognition by the RIG-I like receptor MDA5. Arch. Biochem. Biophys. 2009, 488:23-33.
59. Züst R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., Szretter K.J., Baker S.C., Barchet W., Diamond M.S., Siddell S.G., Ludewig B., Thiel V. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011, 12:137-143.
60. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205:1601-1610.
61. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 2008, 60:805-812.
62. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
63. Perrot I., Deauvieau F., Massacrier C., Hughes N., Garrone P., Durand I., Demaria O., Viaud N., Gauthier L., Blery M., Bonnefoy-Berard N., Morel Y., Tschopp J., Alexopoulou L., Trinchieri G., Paturel C., Caux C. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J. Immunol. 2010, 185:2080-2088.
64. Sugiyama T., Hoshino K., Saito M., Yano T., Sasaki I., Yamazaki C., Akira S., Kaisho T. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. Int. Immunol. 2008, 20:1-9.
65. Haines D.S., Strauss K.I., Gillespie D.H. Cellular response to double-stranded RNA. J. Cell. Biochem. 1991, 46:9-20.
66. Gowen B.B., Wong M.-H., Jung K.-H., Sanders A.B., Mitchell W.M., Alexopoulou L., Flavell R.A., Sidwell R.W. TLR3 is essential for the induction of protective immunity against punta toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 2007, 178:5200-5208.
67. Lau Y.-F., Tang L.-H., Ooi E.-E. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 2009, 27:1354.
68. Lau Y.F., Tang L.H., Ooi E.E., Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 2010, 406:80-87.
69. Jelinek I., Leonard J.N., Price G.E., Brown K.N., Meyer-Manlapat A., Goldsmith P.K., Wang Y., Venzon D., Epstein S.L., Segal D.M. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 2011, 186:2422-2429.
70. Nakada E., Nakada T.A., Walley K.R., McConechy M., McLaughlin L., von Dadelszen P., Shozu M., Boyd J.H. mRNA induces RANTES production in trophoblast cells via TLR3 only when delivered intracellularly using lipid membrane encapsulation. Placenta 2011, 32:500-505.
71. Robbins M., Judge A., MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009, 19:89-102.
72. Ngoi S.M., Tovey M.G., Vella A.T. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J. Immunol. 2008, 181:7670-7680.
73. McCartney S., Vermi W., Gilfillan S., Cella M., Murphy T.L., Schreiber R.D., Murphy K.M., Colonna M. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp. Med. 2009, 206:2967-2976.
74. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
75. Jin B., Sun T., Yu X.-H., Liu C.-Q., Yang Y.-X., Lu P., Fu S.-F., Qiu H.-B., Yeo A.E.T. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J. Biomed. Biotechnol. 2010, 2010. (article ID 690438, 690417 pages).
76. + T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010, 28:7256-7266.
77. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., Schulte R., Gissmann L., Muller M., Sacher A., Racz P., Steinman R.M., Uguccioni M., Ignatius R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5:e1000373.
78. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., Breton G., Trumpfheller C., Pollak S., Shimeliovich I., Duque-Alarcon A., Pan L., Nelkenbaum A., Salazar A.M., Schlesinger S.J., Steinman R.M., Sekaly R.P. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208:2357-2366.
79. Cella M., Salio M., Sakakibara Y., Langen H., Julkunen I., Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 1999, 189:821-829.
80. Verdijk R.M., Mutis T., Esendam B., Kamp J., Melief C.J.M., Brand A., Goulmy E. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 1999, 163:57-61.
81. Hafner A.M., Burschowsky D., Corthesy B., Textor M., Merkle H.P. Surface assembly of poly(I:C) on PEGylated microspheres to shield from adverse interactions with fibroblasts. J. Control. Release 2012, 159:204-214.
82. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., Odermatt B., Conrad C., Ittner L.M., Bauer S., Luther S.A., Uematsu S., Akira S., Hengartner H., Zinkernagel R.M. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005, 11:138-145.
83. Black A.P., Jones L., Malavige G.N., Ogg G.S. Immune evasion during varicella zoster virus infection of keratinocytes. Clin. Exp. Dermatol. 2009, 34:e941-e944.
84. Zhu X., Nishimura F., Sasaki K., Fujita M., Dusak J.E., Eguchi J., Fellows-Mayle W., Storkus W.J., Walker P.R., Salazar A.M., Okada H. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 2007, 5:10.
85. Papi A., Stanciu L.A., Papadopoulos N.G., Teran L.M., Holgate S.T., Johnston S.L. Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells. J. Infect. Dis. 2000, 181:1780-1784.
86. Steinmassl M., Hamprecht K. Double fluorescence analysis of human cytomegalovirus (HCMV) infected human fibroblast cultures by flow cytometry: increase of class I MHC expression on uninfected cells and decrease on infected cells. Arch. Virol. 1994, 135:75-87.
87. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 1993, 54:1-78.
88. Smith R.S., Smith T.J., Blieden T.M., Phipps R.P. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am. J. Pathol. 1997, 151:317-322.
89. Anders H.J., Zecher D., Pawar R.D., Patole P.S. Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Res. Ther. 2005, 7:215-224.
90. Kohn L.D., Shimojo N., Kohno Y., Suzuki K. An animal model of Graves' disease: understanding the cause of autoimmune hyperthyroidism. Rev. Endocr. Metab. Disord. 2000, 1:59-67.
91. Sobel D.O., Newsome J., Ewel C.H., Bellanti J.A., Abbassi V., Creswell K., Blair O. Poly(I:C) induces development of diabetes mellitus in BB rat. Diabetes 1992, 41:515-520.
92. Ewel C.H., Sobel D.O., Zeligs B.J., Bellanti J.A. Poly(I:C) accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes 1992, 41:1016-1021.
93. Okada C., Akbar S.M., Horiike N., Onji M. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int. 2005, 25:595-603.
94. Patole P.S., Grone H.J., Segerer S., Ciubar R., Belemezova E., Henger A., Kretzler M., Schlondorff D., Anders H.J. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 2005, 16:1326-1338.
95. Sobel D.O., Goyal D., Ahvazi B., Yoon J.W., Chung Y.H., Bagg A., Harlan D.M. Low dose poly(I:C) prevents diabetes in the diabetes prone BB rat. J. Autoimmun. 1998, 11:343-352.
96. Suzuki K., Mori A., Ishii K.J., Saito J., Singer D.S., Klinman D.M., Krause P.R., Kohn L.D. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2285-2290.
97. Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G., Gamble D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 1985, 313:353-360.
98. Jackson R., McNicol A.M., Farquharson M., Foulis A.K. Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease. J. Pathol. 1988, 155:113-120.
99. Freeman A.I., Al-Bussam N., O'Malley J.A., Stutzman L., Bjornsson S., Carter W.A. Pharmacologic effects of polyinosinic-polycytidylic acid in man. J. Med. Virol. 1977, 1:79-93.
100. Cunningham C., Campion S., Teeling J., Felton L., Perry V.H. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav. Immun. 2007, 21:490-502.
101. Fortier M.E., Kent S., Ashdown H., Poole S., Boksa P., Luheshi G.N. The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R759-R766.
102. Katafuchi T., Kondo T., Yasaka T., Kubo K., Take S., Yoshimura M. Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 2003, 120:837-845.
103. Jin B., Wang R.Y., Qiu Q., Sugauchi F., Grandinetti T., Alter H.J., Shih J.W. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 2007, 122:15-27.
104. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., Bosio C., Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 2006, 176:7335-7345.
105. + T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 2011, 150:307-317.
106. Straub S.X., Garry R.F., Magee W.E. Interferon induction by poly(I):poly(C) enclosed in phospholipid particles. Infect. Immun. 1974, 10:783-792.
107. Sokolova V., Knuschke T., Kovtun A., Buer J., Epple M., Westendorf A.M. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 2010, 31:5627.
108. Tincer G., Yerlikaya S., Yagci F.C., Kahraman T., Atanur O.M., Erbatur O., Gursel I. Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. Biomaterials 2011, 32:4275-4282.
109. + T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials 2009, 30:910-918.
110. Wischke C., Zimmermann J., Wessinger B., Schendler A., Borchert H.H., Peters J.H., Nesselhut T., Lorenzen D.R. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm. 2009, 365:61-68.
111. Hafner A.M., Corthésy B., Textor M., Merkle H.P. Tuning the immune response of dendritic cells to surface-assembled poly(I:C) on microspheres through synergistic interactions between phagocytic and TLR3 signaling. Biomaterials 2011, 32:2651-2661.
112. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
113. Hashida M., Egawa M., Muranishi S., Sezaki H. Role of intramuscular administration of water-in-oil emulsions as a method for increasing the delivery of anticancer agents to regional lymphatics. J. Pharmacokinet. Biopharm. 1977, 5:225-239.
114. Altin J.G., Parish C.R. Liposomal vaccines-targeting the delivery of antigen. Methods 2006, 40:39-52.
115. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., Agger E.M., Andersen P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 2005, 1718:22-31.
116. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., Agger E.M., Stenger S., Andersen P., Ruland J., Brown G.D., Wells C., Lang R. Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 2010, 184:2756-2760.
117. Templeton N.S. Cationic liposome-mediated gene delivery in vivo. Biosci. Rep. 2002, 22:283-295.
118. Oussoren C., Zuidema J., Crommelin D.J., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1997, 1328:261-272.
119. Oussoren C., Zuidema J., Crommelin D.J.A., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous Injection. I. Influence of the anatomical site of injection. J. Liposome Res. 1997, 7:85-99.
120. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine 2008, 3:133-149.
121. Sokolova V.V., Radtke I., Heumann R., Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006, 27:3147-3153.
122. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59:478-490.
123. Bondi M.L., Craparo E.F. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin. Drug Deliv. 2010, 7:7-18.
124. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
125. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16:2298-2307.
126. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 2006, 112:26-34.
127. Peyre M., Fleck R., Hockley D., Gander B., Sesardic D. In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine 2004, 22:2430-2437.
128. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 2002, 60:480-486.
129. Williams-Herman D., Werb Z., Siamon G. Phagocytosis by nonprofessional phagocytes. Advances in Cellular and Molecular Biology of Membranes and Organelles 1999, 47-67. JAI Press, Stamford, CT. S. Gordon (Ed.).
130. Waeckerle-Men Y., Uetz-von Allmen E., Gander B., Scandella E., Schlosser E., Schmidtke G., Merkle H.R., Groettrup M. Encapsulation of proteins and peptides into biodegradable poly(d,l-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006, 24:1847-1857.
131. Men Y., Gander B., Merkle H.P., Corradin G. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 1996, 14:1442-1450.
132. Men Y., Thomasin C., Merkle H.P., Gander B., Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995, 13:683-689.
133. Men Y., Tamber H., Audran R., Gander B., Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 1997, 15:1405-1412.
134. Evans J.T., Ward J.R., Kern J., Johnson M.E. A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against mycobacterium tuberculosis antigen Mtb8.4. Vaccine 2004, 22:1964-1972.
135. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., Gander B., Corradin G. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21:1250-1255.
136. Waeckerle-Men Y., Scandella E., Allmen E.U., Ludewig B., Gillessen S., Merkle H.P., Gander B., Groettrup M. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J. Immunol. Methods 2004, 287:109-124.
137. Fischer S., Uetz-von Allmen E., Waeckerle-Men Y., Groettrup M., Merkle H.P., Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007, 28:994-1004.
138. Wischke C., Borchert H.H., Zimmermann J., Siebenbrodt I., Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J. Control. Release 2006, 114:359-368.
139. Haining W.N., Anderson D.G., Little S.R., von Bergwelt-Baildon M.S., Cardoso A.A., Alves P., Kosmatopoulos K., Nadler L.M., Langer R., Kohane D.S. pH-triggered microparticles for peptide vaccination. J. Immunol. 2004, 173:2578-2585.
140. Wattendorf U., Coullerez G., Voros J., Textor M., Merkle H.P. Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells. Langmuir 2008, 24:11790-11802.
141. Brandhonneur N., Chevanne F., Vie V., Frisch B., Primault R., Le Potier M.F., Le Corre P. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 2009, 36:474-485.
142. Thiele L., Merkle H.P., Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 2003, 20:221-228.
143. Gomez J.M.M., Csaba N., Fischer S., Sichelstiel A., Kundig T.M., Gander B., Johansen P. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J. Control. Release 2008, 130:161-167.
144. Wattendorf U., Merkle H.P. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 2008, 97:4655-4669.
145. Wattendorf U., Koch M.C., Walter E., Voeroes J., Textor M., Merkle H.P. Phagocytosis of poly(l-lysine)-graft-poly(ethylene glycol)-coated microspheres by antigen presenting cells: Impact of grafting ratio and poly(ethylene glycol) chain length on cellular recognition. Biointerphases 2006, 1:123-133.
146. Wattendorf U., Kreft O., Textor M., Sukhorukov G.B., Merkle H.P. Stable stealth function for hollow polyelectrolyte microcapsules through a poly(ethylene glycol) grafted polyelectrolyte adlayer. Biomacromolecules 2008, 9:100-108.
147. Preis I., Langer R.S. A single-step immunization by sustained antigen release. J. Immunol. Methods 1979, 28:193-197.
148. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57:357-376.
149. Cleland J.L. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 1999, 17:25-29.
150. Fischer S., Foerg C., Ellenberger S., Merkle H.P., Gander B. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. J. Control. Release 2006, 111:135-144.
151. Erni C., Suard C., Freitas S., Dreher D., Merkle H.P., Walter E. Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials 2002, 23:4667-4676.
152. Tafaghodi M., Sajadi Tabasi S.A., Jaafari M.R. Formulation, characterization and release studies of alginate microspheres encapsulated with tetanus toxoid. J. Biomater. Sci. Polym. Ed. 2006, 17:909-924.
153. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14:201-207.
154. Kang M.L., Cho C.S., Yoo H.S. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol. Adv. 2009, 27:857-865.
155. Johansen P., Men Y., Merkle H.P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 2000, 50:129-146.
156. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv. Drug Deliv. Rev. 2005, 57:475-482.
157. Jain S., O'Hagan D.T., Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev. Vaccines 2011, 10:1731-1742.
158. Thomasin C., Corradin G., Men Y., Merkle H.P., Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 1996, 41:131.
159. Gander B., Wehrli E., Alder R., Merkle H.P. Quality improvement of spray-dried, protein-loaded d,l-PLA microspheres by appropriate polymer solvent selection. J. Microencapsul. 1995, 12:83-97.
160. Freitas S., Merkle H.P., Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control. Release 2005, 102:313-332.
161. Freitas S., Walz A., Merkle H.P., Gander B. Solvent extraction employing a static micromixer: a simple, robust and versatile technology for the microencapsulation of proteins. J. Microencapsul. 2003, 20:67-85.
162. Freitas S., Rudolf B., Merkle H.P., Gander B. Flow-through ultrasonic emulsification combined with static micromixing for aseptic production of microspheres by solvent extraction. Eur. J. Pharm. Biopharm. 2005, 61:181-187.
163. Walter E., Merkle H.P. Microparticle-mediated transfection of non-phagocytic cells in vitro. J. Drug Target. 2002, 10:11-21.
164. Jilek S., Merkle H.P., Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev. 2005, 57:377-390.
165. Hafner A.M. Immunobiology of Surface-assembled Poly(I:C) on Microspheres as Safe and Efficacious Immunostimulant in Vaccination 2012, PhD thesis, ETH Zurich. 10.3929/ethz-a-007326128.
166. Walter E., Moelling K., Pavlovic J., Merkle H.P. Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. J. Control. Release 1999, 61:361-374.
167. Yang S.C., Bhide M., Crispe I.N., Pierce R.H., Murthy N. Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug. Chem. 2008, 19:1164-1169.
168. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O'Hagan D.T., Petrilli V., Tschopp J., O'Neill L.A., Lavelle E.C. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:870-875.
169. Wesa A.K., Galy A. IL-1 beta induces dendritic cells to produce IL-12. Int. Immunol. 2001, 13:1053-1061.
170. Tominaga K., Yoshimoto T., Torigoe K., Kurimoto M., Matsui K., Hada T., Okamura H., Nakanishi K. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int. Immunol. 2000, 12:151-160.